Covered recipient · General Payments record
HENRIK BO ILLUM
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$466.63
22 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $466.63 | 22 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $140.44 | 7 |
| Novartis Pharmaceuticals Corporation | $45.40 | 3 |
| EMD Serono, Inc. | $30.94 | 1 |
| Daiichi Sankyo Inc. | $29.60 | 1 |
| Medtronic, Inc. | $29.42 | 1 |
| Tempus AI, Inc | $26.70 | 1 |
| Janssen Biotech, Inc. | $25.27 | 1 |
| SOBI, INC | $24.49 | 1 |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 1 |
| ARRAY BIOPHARMA INC | $23.03 | 1 |
| PFIZER INC. | $20.85 | 1 |
| GlaxoSmithKline, LLC. | $17.57 | 1 |
| Agios Pharmaceuticals, Inc. | $14.95 | 1 |
| Kite Pharma, Inc. | $14.59 | 1 |
Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HENRIK BO ILLUM
NPI 1982805164 · CMS profile ID 818448
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BEDFORD, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1982805164?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
22 matching records · $466.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–22 of 22.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC | $23.03 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132134567 | CMS |
| Celgene Corporation | $15.30 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093774 | CMS |
| Daiichi Sankyo Inc. | $29.60 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089436146 | CMS |
| Novartis Pharmaceuticals Corporation | $16.40 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086785883 | CMS |
| Medtronic, Inc. | $29.42 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119579213 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101264625 | CMS |
| EMD Serono, Inc. | $30.94 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120243561 | CMS |
| Celgene Corporation | $20.81 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093762 | CMS |
| Celgene Corporation | $22.37 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093760 | CMS |
| GlaxoSmithKline, LLC. | $17.57 | 07/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116471264 | CMS |
| Janssen Biotech, Inc. | $25.27 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078693941 | CMS |
| Tempus AI, Inc | $26.70 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150166630 | CMS |
| Celgene Corporation | $23.32 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093754 | CMS |
| Celgene Corporation | $23.80 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093752 | CMS |
| Celgene Corporation | $11.04 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093750 | CMS |
| SOBI, INC | $24.49 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141419478 | CMS |
| PFIZER INC. | $20.85 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131300152 | CMS |
| Celgene Corporation | $23.80 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101093742 | CMS |
| Novartis Pharmaceuticals Corporation | $13.24 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086785881 | CMS |
| Agios Pharmaceuticals, Inc. | $14.95 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149645548 | CMS |
| Kite Pharma, Inc. | $14.59 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128613455 | CMS |
| Novartis Pharmaceuticals Corporation | $15.76 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086785879 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $30,785.70 | 23 |
| PY2024 | Principal investigator | $56,382.74 | 49 |
| PY2023 | Principal investigator | $148,965.97 | 74 |
| PY2022 | Principal investigator | $217,097.35 | 91 |
| PY2021 | Principal investigator | $222,524.42 | 113 |
| PY2020 | Principal investigator | $248,821.20 | 67 |
| PY2019 | Recipient | $1,250.00 | 1 |
| PY2019 | Principal investigator | $428,314.17 | 79 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
113 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eisai Inc. | $1,020.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174389 |
| Principal investigator 1 | Eisai Inc. | $1,020.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174395 |
| Principal investigator 1 | Eisai Inc. | $1,020.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174407 |
| Principal investigator 1 | Eisai Inc. | $1,009.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174537 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740827 |
| Principal investigator 1 | MorphoSys AG | $40.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740839 |
| Principal investigator 1 | MorphoSys AG | $295.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740851 |
| Principal investigator 1 | MorphoSys AG | $1,859.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740857 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740863 |
| Principal investigator 1 | MorphoSys AG | $100.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740869 |
| Principal investigator 1 | MorphoSys AG | $200.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740881 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740887 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740893 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740897 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740909 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740915 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740921 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740927 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740933 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740940 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 12/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741114 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174501 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740787 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740799 |
| Principal investigator 1 | MorphoSys AG | $1,592.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740821 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741063 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741079 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741085 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741091 |
| Principal investigator 1 | MorphoSys AG | $982.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741121 |
| Principal investigator 1 | Seagen Inc. | $182.00 | 11/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668991 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY P.A. | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 842915541 |
| Principal investigator 1 | Eisai Inc. | $300.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174399 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174477 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174527 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836174549 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 836175089 |
| Principal investigator 1 | MorphoSys AG | $982.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740203 |
| Principal investigator 1 | MorphoSys AG | $1,275.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740215 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740221 |
| Principal investigator 1 | MorphoSys AG | $312.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740263 |
| Principal investigator 1 | MorphoSys AG | $2,587.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740269 |
| Principal investigator 1 | MorphoSys AG | $100.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740741 |
| Principal investigator 1 | MorphoSys AG | $166.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740747 |
| Principal investigator 1 | MorphoSys AG | $1,532.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740759 |
| Principal investigator 1 | MorphoSys AG | $1,737.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740765 |
| Principal investigator 1 | MorphoSys AG | $500.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740769 |
| Principal investigator 1 | MorphoSys AG | $200.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740775 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740963 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740969 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740987 |
| Principal investigator 1 | MorphoSys AG | $842.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740997 |
| Principal investigator 1 | MorphoSys AG | $125.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854741039 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 827904951 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $638.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498989 |
| Principal investigator 1 | Seagen Inc. | $180.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668765 |
| Principal investigator 1 | Seagen Inc. | $480.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668767 |
| Principal investigator 1 | Seagen Inc. | $180.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792669011 |
| Principal investigator 1 | Seagen Inc. | $180.00 | 10/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792669013 |
| Principal investigator 1 | BeiGene, Ltd. | $1,125.00 | 10/04/2021 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 843874753 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 09/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836175085 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174281 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174285 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174379 |
| Principal investigator 1 | MorphoSys AG | $6,800.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 854740127 |
| Principal investigator 1 | Seagen Inc. | $169.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668999 |
| Principal investigator 1 | Seagen Inc. | $182.00 | 08/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792669001 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 07/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY P.A. | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 842899603 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 07/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174313 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 07/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 827904891 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $638.00 | 07/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498987 |
| Principal investigator 1 | BeiGene, Ltd. | $1,125.00 | 06/30/2021 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 843874721 |
| Principal investigator 1 | Acerta Pharma LLC | $6,250.00 | 06/18/2021 | Non-covered Recipient Entity US ONCOLOGY RESEARCH | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 826486999 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,250.00 | 06/18/2021 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 819905843 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 06/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174237 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 06/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174261 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $190.00 | 06/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498985 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $390.00 | 05/25/2021 | Non-covered Recipient Entity US ONCOLOGY | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DISEASE | No dispute reported | 06/30/2026 | 800649285 |
| Principal investigator 1 | Eisai Inc. | $300.00 | 05/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174297 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 05/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174301 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 05/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174711 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $190.00 | 05/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498983 |
| Principal investigator 1 | Amgen Inc. | $2,823.42 | 04/27/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY-BEDFORD | AMG 510_Ph3 NSCLC Monotherapy Comparator Trial | No dispute reported | 06/30/2026 | 830979887 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY P.A. | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 842900037 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174705 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 827904809 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $190.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498979 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $638.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498981 |
| Principal investigator 1 | Seagen Inc. | $275.00 | 04/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668683 |
| Principal investigator 1 | BeiGene, Ltd. | $1,125.00 | 04/05/2021 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 843874687 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 03/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174791 |
| Principal investigator 1 | Eisai Inc. | $1,088.00 | 03/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836175037 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 03/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836175054 |
| Principal investigator 1 | BeiGene, Ltd. | $13,265.00 | 03/03/2021 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 843874661 |
| Principal investigator 1 | Celgene Corporation | $714.00 | 02/15/2021 | Non-covered Recipient Entity Texas Oncology | Connect MM- The Multiple Myeloma Disease Registry | No dispute reported | 06/30/2026 | 807115677 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 02/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174752 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,838.00 | 02/04/2021 | Non-covered Recipient Entity Us Oncology Res Llc | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices | No dispute reported | 06/30/2026 | 819905055 |
| Principal investigator 1 | Amgen Inc. | $13,200.00 | 01/21/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY-BEDFORD | AMG 510_Ph3 NSCLC Monotherapy Comparator Trial | No dispute reported | 06/30/2026 | 830979885 |
| Principal investigator 1 | Amgen Inc. | $1,700.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY-BEDFORD | AMG 510_Ph3 NSCLC Monotherapy Comparator Trial | No dispute reported | 06/30/2026 | 830979883 |
| Principal investigator 1 | Celgene Corporation | $1,666.00 | 01/15/2021 | Non-covered Recipient Entity Texas Oncology | Connect MM- The Multiple Myeloma Disease Registry | No dispute reported | 06/30/2026 | 807115665 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,228.00 | 01/15/2021 | Non-covered Recipient Entity Texas Oncology | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | No dispute reported | 06/30/2026 | 819901665 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $21,755.00 | 01/15/2021 | Non-covered Recipient Entity Texas Oncology | Phase II III 1L CRC Nivo CT w pt segmentation rational combos | No dispute reported | 06/30/2026 | 819901683 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,824.00 | 01/15/2021 | Non-covered Recipient Entity Texas Oncology | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices | No dispute reported | 06/30/2026 | 819901689 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,275.00 | 01/15/2021 | Non-covered Recipient Entity Texas Oncology | Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 819901757 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY P.A. | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 842899799 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174565 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174677 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 836174681 |
| Principal investigator 1 | Novocure Inc. | $850.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 827904765 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $638.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | No dispute reported | 06/30/2026 | 786498977 |
| Principal investigator 1 | Seagen Inc. | $275.00 | 01/15/2021 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 792668671 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $41,736.00 | 01/14/2021 | Non-covered Recipient Entity Us Oncology Res Llc | Phase II III 1L MSS CRC Nivo SOC vs SOC | No dispute reported | 06/30/2026 | 819905249 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,363.00 | 01/13/2021 | Non-covered Recipient Entity Us Oncology Res Llc | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | No dispute reported | 06/30/2026 | 819905575 |